共 88 条
[1]
Holman RR(1998)Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 837-853
[2]
Paul SK(2008)10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 359 1577-1589
[3]
Bethel MA(2015)Excess mortality among persons with type 2 diabetes N Engl J Med 373 1720-1732
[4]
Matthews DR(2016)Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors Diabetes Obes Metab 18 203-216
[5]
Neil HA(2007)Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications Diabetes Care 30 1344-1350
[6]
Tancredi M(2009)Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin—diabetes control and potential adverse events Best Pract Res Clin Endocrinol Metab. 23 487-498
[7]
Rosengren A(2010)Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial Lancet 375 1447-1456
[8]
Svensson AM(2011)One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial Int J Clin Pract 65 397-407
[9]
Nauck M(2005)Understanding randomised controlled trials Arch Dis Child 90 840-844
[10]
Ahren B(2014)Cost effectiveness of liraglutide in type II diabetes: a systematic review Pharmacoeconomics 32 1079-1091